MAP2K7 and non-small cell lung carcinoma: Similarly, an in silico approach using public datasets identified protein tyrosine kinase PTK7 as a potential oncogenic driver in non-small cell lung cancer (NSCLC); these findings were validated in vitro and in vivo, where PTK7 was found to regulate MKK7-JNK signalling, indicating its utility as a potential therapeutic target [35].